01828nas a2200325   4500000000100000008004100001260001300042653002200055653002000077653001200097653004000109653001100149653002300160653001100183653001200194653001300206653000900219653002000228653001400248653003000262100001600292700001300308700001700321700001700338245005900355300001100414490000700425520105600432022001401488       1984                            d  c1984 Jan10aAfrican Americans10aAsian Americans10aDapsone10aEuropean Continental Ancestry Group10aFemale10aHispanic Americans10aHumans10aleprosy10aLymphoma10aMale10aMouth Neoplasms10aNeoplasms10aUrinary Bladder Neoplasms1 aBrinton L A1 aHoover R1 aJacobson R R1 aFraumeni J F00aCancer mortality among patients with Hansen's disease.  a109-140 v723 a<p>For the evaluation of cancer risks associated with immunodeficiencies experienced by patients with Hansen's disease (leprosy) and for the assessment of possible adverse effects of dapsone therapy, a follow-up study was conducted of 1,678 patients admitted to the National Hansen's Disease Center in Carville, La., between 1939 and 1977. Overall, no substantial cancer mortality was observed (standardized mortality ratio = 1.3), nor was there any excess among patients exhibiting defects in cellular immunity by virtue of lepromatous forms of the disease. Notable was the absence of any significant excess of lymphoma (5 observed vs. 2.3 expected), despite the predominance of this tumor in certain other immunodeficiency states. Several cancer sites (oral, bladder, and kidney) occurred excessively, but reasons for the elevations were obscure. Although dapsone has been implicated as a carcinogen in laboratory animals, the use of sulfones, including dapsone, did not appear to affect significantly the risk of any cancers in this population.</p>  a0027-8874